Today: 19 July 2026
Monolithic Power Systems (MPWR) stock slides Monday — after a record close, traders eye dividend hike and CFO shift
9 February 2026
1 min read

Monolithic Power Systems (MPWR) stock slides Monday — after a record close, traders eye dividend hike and CFO shift

New York, Feb 9, 2026, 12:58 EST — Regular session

  • MPWR slid roughly 2% by midday, pulling back after reaching a new intraday high earlier Monday.
  • The dip comes after last week’s earnings topped forecasts, the company boosted its dividend, and it outlined a new CFO succession plan.
  • Next up for investors: timing on the 2025 annual report (Form 10-K) and the March 31 dividend record date.

Shares of Monolithic Power Systems dropped 1.9% to $1,206.09 on Monday. The move pulled back some of the power-management chipmaker’s gains from its post-earnings surge. The stock changed hands in a range between $1,180.93 and $1,236.14 during the day.

This shift stands out as MPWR just saw a significant repricing. With last week’s beat-and-raise, shares now assume smooth sailing—meaning even a standard shakeup can send a signal.

Friday saw MPWR surge 6.4%, finishing at $1,229.82—a fresh 52-week high, with traders driving the stock up ahead of the weekend.

Monolithic reported Feb. 5 that revenue climbed 20.8% year over year to $751.2 million for the quarter. Adjusted net income, which strips out some items, came in at $235.3 million, or $4.79 a share on a diluted basis. CEO Michael Hsing called the results evidence of Monolithic’s “continued success in transforming from a chip-only, semiconductor supplier to a full service, silicon-based solutions provider.”

The company bumped its quarterly cash dividend up to $2.00 per share, from the previous $1.56. Shareholders on record as of the close of March 31 are set to receive the payout on April 15.

Monolithic also put out word of a finance leadership shakeup. CFO Bernie Blegen plans to retire after the company’s 2025 annual report on Form 10-K—where the audited numbers and risk factors get laid out—hits the books. Corporate controller Rob Dean will fill the CFO seat on an interim basis. “In his ten years as CFO, MPS has grown consistently at an above-market growth rate,” Hsing said. nasdaq.com

Analysts are bumping up their targets after the results. Over at Needham, N. Quinn Bolton moved his price target to $1,300 on Feb. 6, GuruFocus reports.

There was also a fresh blip from insider activity. On Feb. 6, officer Maurice Sciammas filed a Form 144, signaling a plan to unload 1,286 shares. Form 144 gives advance notice of a potential insider sale—though it’s just an intention, not a done deal.

Action in chip stocks split on Monday, with Monolithic charting its own course. Texas Instruments edged down 0.4%. Analog Devices and NXP Semiconductors saw modest gains.

Still, there’s risk on the flip side. MPWR has surged to a point where even a slight slip—whether in demand or margins—could sting, given how fully priced the stock is. Any miss on those March-quarter goals, and investors might feel it more than usual.

Investors are watching for when the 2025 Form 10-K lands—that filing sets off the CFO handover. They’re also keeping an eye on March 31, the record date for the bigger dividend, with the payout scheduled for April 15.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • CSL Recovers A$16 Billion in Value, Trails Plasma Sector Gains This Week
    July 19, 2026, 3:25 PM EDT. CSL Limited (ASX:CSL) finished July 17 at A$123.32, rising 1.12% on the session and 0.35% for the week, recovering 37% from its 52-week low at A$90 and regaining roughly A$16 billion in valuation. However, CSL underperformed plasma specialists Grifols SA (+1.95%) and Takeda Pharmaceutical (+2.26%) in weekly movement. Trading volume for CSL on Friday came in 14% under its average as 1.62 million shares changed hands. The full-year financial results are due August 18. Still 55% beneath its 52-week peak, CSL's market value stands at A$59.06 billion. The group forecasts FY26 revenues near US$15.2 billion and NPATA of about US$3.1 billion, while a US$5 billion impairment remains subject to audit and board sign-off.
Merck stock is inches from a 52-week high — and an insider just sold shares
Previous Story

Merck stock is inches from a 52-week high — and an insider just sold shares

Dauch (DCH) stock rises in early trade as board changes and exec share award hit filings
Next Story

Dauch (DCH) stock rises in early trade as board changes and exec share award hit filings

Go toTop